Orfiril 150 (Sodium Valproate)

Sodium Valproate, the active ingredient in Orfiril 150, is an anticonvulsant presented as a 150 mg tablet for oral use. It is employed in the management of epilepsy and related seizure disorders in adults and children. GNH USA supplies Orfiril 150 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Orfiril 150 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orfiril 150 is an antiepileptic drug that acts on neuronal excitability to control various seizure types.

- Generalised tonic‑clonic seizures: reduces frequency and severity of convulsive episodes. - Absence seizures: helps achieve seizure‑free periods in patients with typical absence epilepsy. - Myoclonic seizures: diminishes myoclonic jerks and improves daily functioning. - Lennox‑Gastaut syndrome: contributes to overall seizure control in this severe epilepsy syndrome. - Bipolar disorder (off‑label): stabilises mood and prevents manic episodes when prescribed by a psychiatrist.

Adverse reactions to sodium valproate may vary in frequency and severity.

Common Side Effects: - Nausea or vomiting: mild gastrointestinal upset. - Tremor: fine shaking of the hands. - Weight gain: gradual increase in body weight. - Hair loss: diffuse thinning of scalp hair. - Drowsiness: transient sedation. - Elevated liver enzymes: mild, often reversible changes.

Serious or Rare Side Effects: - Hepatic failure: severe liver injury, especially in young children. - Pancreatitis: inflammation of the pancreas with abdominal pain. - Thrombocytopenia: low platelet count leading to bleeding risk. - Hyperammonemia: elevated blood ammonia causing confusion. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Birth defects: teratogenic risk when used during pregnancy.

When prescribing sodium valproate, clinicians should consider several safety aspects.

- Liver function monitoring: assess baseline enzymes and repeat periodically. - Pregnancy risk: avoid use in women of childbearing potential unless no alternative exists. - Drug interactions: review concomitant medications for potential PK/PD effects. - Renal function: adjust dosing in severe impairment. - Hematologic monitoring: check complete blood count for thrombocytopenia. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Sodium valproate interacts with several medicines, requiring careful management.

Major Interactions (Avoid): - Carbamazepine: may reduce valproate levels and increase hepatotoxic risk. - Phenobarbital: can lower valproate concentrations, diminishing efficacy. - Rifampicin: induces metabolism, leading to sub‑therapeutic levels.

Moderate Interactions (Monitor Closely): - Oral contraceptives: valproate may increase hormone levels, altering contraceptive effectiveness. - Warfarin: enhanced anticoagulant effect may require INR monitoring. - Lamotrigine: risk of severe skin reactions when combined. - Topiramate: may increase risk of hyperammonemia. - Acetaminophen: high doses can raise liver enzyme levels.